Difference between revisions of "Glycoprotein non-metastatic B"
Jump to navigation
Jump to search
(Created page with "'''Glycoprotein non-metastatic B''', abbreviated '''GPNMB''', is an immunostain. It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.<ref name=pmid37...") |
(carete) |
||
| Line 3: | Line 3: | ||
It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.<ref name=pmid37661807>{{cite journal |authors=Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, Matoso A |title=Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others |journal=Am J Surg Pathol |volume=47 |issue=11 |pages=1267–1273 |date=November 2023 |pmid=37661807 |doi=10.1097/PAS.0000000000002117 |url=}}</ref> | It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.<ref name=pmid37661807>{{cite journal |authors=Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, Matoso A |title=Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others |journal=Am J Surg Pathol |volume=47 |issue=11 |pages=1267–1273 |date=November 2023 |pmid=37661807 |doi=10.1097/PAS.0000000000002117 |url=}}</ref> | ||
==Positive== | |||
*[[Angiomyolipoma]]. | |||
*[[TFE3-rearranged renal cell carcinoma]]. | |||
*[[TFEB-rearranged renal cell carcinoma]]. | |||
*[[Low-grade oncocytic tumour]] (LOT). | |||
*[[PEComa]]. | |||
*[[RCC with FMS]]. | |||
==References== | ==References== | ||
Revision as of 13:27, 26 March 2024
Glycoprotein non-metastatic B, abbreviated GPNMB, is an immunostain.
It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.[1]
Positive
- Angiomyolipoma.
- TFE3-rearranged renal cell carcinoma.
- TFEB-rearranged renal cell carcinoma.
- Low-grade oncocytic tumour (LOT).
- PEComa.
- RCC with FMS.
References
- ↑ Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, Matoso A (November 2023). "Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others". Am J Surg Pathol 47 (11): 1267–1273. doi:10.1097/PAS.0000000000002117. PMID 37661807.